Welcome to our dedicated page for Retractable Tech SEC filings (Ticker: RVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Retractable Technologies, Inc. (RVP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Retractable’s filings, including Form 10-K annual reports, Form 10-Q quarterly reports, and Form 8-K current reports, describe its business of manufacturing and marketing VanishPoint®, EasyPoint®, and Patient Safe® safety medical products, as well as key financial and operational details.
In its periodic reports, Retractable discusses net sales, operating income or loss, domestic and international revenue mix, and the influence of product mix between VanishPoint® syringes and EasyPoint® needles on average selling prices and margins. The filings also address the material impact of tariffs on needles, syringes, and other products imported from China, and explain how these costs are reflected in cost of manufactured product. Disclosures describe the company’s efforts to increase U.S.-based manufacturing, adapt equipment for domestic production, and adjust its workforce in response to tariff pressures.
Form 8-K current reports for RVP document material events such as quarterly and annual results announcements, preferred stock dividend declarations for Series II Class B and Series III Class B Convertible Preferred Stock, workforce reductions, and product-related recognitions. These filings confirm that Retractable’s common stock is registered on NYSE American under the symbol RVP and that the company is incorporated in Texas.
On Stock Titan, users can review these SEC filings with AI-powered summaries that highlight key points from lengthy documents, such as discussions of tariffs, product mix, liquidity considerations, and risk factors related to patent protection, supplier relationships, foreign trade risk, access to markets, production costs, and competition from larger safety device providers. The platform also surfaces updates in near real time as new filings are posted to EDGAR, helping users quickly see changes in Retractable’s reported results, capital structure, or material events.
By combining the full text of RVP’s SEC filings with AI-generated explanations, this page is intended to make it easier to understand how Retractable’s safety medical device business, financial performance, and risk disclosures are presented in its official regulatory documents.
Retractable Technologies (RVP) filed a Form 4 showing that President, CEO, Director and 10% owner Thomas J. Shaw bought 1,575 common shares on 08/01/2025 at a weighted-average price of $0.703. The transaction was coded “P” (open-market purchase) and executed under a Rule 10b5-1 plan adopted 08/22/2024.
Following the purchase, Shaw directly owns 15,498,332 shares and holds indirect control over an additional 831,600 shares—bringing his total beneficial interest to roughly 16.3 million shares. The incremental buy represents less than 0.01% of his existing stake, so economic impact is minimal, yet the action reiterates insider alignment at a depressed price level. No derivative security activity was reported.
Retractable Technologies, Inc. (RVP) – Form 4 insider transaction
President, CEO, Director and 10% owner Thomas J. Shaw reported an open-market purchase (transaction code P) of company common stock on 30 June 2025. Shaw acquired 1,347 shares at a weighted-average price of $0.6221 per share pursuant to a Rule 10b5-1 trading plan adopted on 22 Aug 2024.
- Direct ownership after the trade: 15,442,020 shares
- Indirect ownership (trust & voting agreement): 831,600 shares
- Total reported beneficial ownership (direct + indirect): 16,273,620 shares
No derivative securities were reported in Table II. The filing indicates Shaw remains a key insider (Director, CEO, 10% holder) and the form was signed on 1 July 2025.